Navigation Links
Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer
Date:7/24/2014

LAWRENCEVILLE, N.J., July 24, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC).  The trial is designed to enroll 20 patients at several U.S. clinical sites and is evaluating ThermoDox in combination with mild hyperthermia. Of the 13 patients enrolled and treated, 10 were eligible for evaluation of efficacy.  Based on data available to date, 60% of patients experienced a stabilization of their highly refractory disease with a local response rate of 50% observed in the 10 evaluable patients, notably 3 complete responses (CR), 2 partial responses (PR) and 1 patient with stable disease (SD). 

These data are consistent with the previously reported positive Phase 1 data in RCWBC.  Celsion previously reported combined clinical data from two Phase I trials, the Company's Phase 1 DIGNITY Study and the Duke University sponsored Phase I trial of ThermoDox® plus hyperthermia in RCWBC in December 2013. The two similarly designed Phase I studies enrolled patients with highly resistant tumors found on the chest wall and who had progressed on previous therapy including chemotherapy, radiation therapy and hormone therapy.  There were 29 patients treated in the two trials (11 patients in the Company's DIGNITY study and 18 patients in the Duke study).  Of the 29 patients treated, 23 were eligible for evaluation of efficacy.  A local response rate of over 60% was reported in 14 of the 23 evaluable patients with 5 complete responses and 9 partial responses.

"These clinical results are very encouraging, given the fact that these patients have failed numerous previous treatments and have limited or no treatment options for this aggressive form of breast
'/>"/>

SOURCE Celsion Corporation
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celsion Corporation to Hold Year-End 2012 Financial Results Conference Call On Monday, March 18, 2013
2. Celsion Corporation Reports Year End 2012 Financial Results and Provides Business Update
3. Celsion Corporation Issues Statement Regarding Misleading Blog Entry
4. Celsion Corporation to Hold Second Quarter 2013 Financial Results Conference Call on Thursday, August 8, 2013
5. Celsion Corporation Reports Second Quarter 2013 Financial Results and Provides HEAT Study Update
6. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast Cancer Conference
7. Celsion Corporation to Hold Third Quarter 2013 Financial Results Conference Call on Tuesday, November 12, 2013
8. Celsion Corporation Reports Third Quarter 2013 Financial Results and Provides Business Update
9. Celsion Corporation Announces Strategic Loan Facility
10. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials at the 2013 San Antonio Breast Cancer Conference
11. Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 WHEN: Wednesday, October 29, 2014 ... available at: http://bit.ly/1yStiU9 SPEAKERS: Visionary ... Visionary Innovation Research Group Senior Research Analyst ... materials, nanobots and flexible electronics are among ... our lives in the coming decades. These ...
(Date:10/22/2014)... Conn. , Oct. 22, 2014  Recently published ... have bolstered the already substantial database of evidence. This ... adoption of Stretta therapy for sufferers of ... clinical evidence supporting Stretta therapy as a ... policies that make Stretta therapy available to nearly 50 ...
(Date:10/20/2014)... MOUNTAIN VIEW, California , 20 de octubre ... un líder en el campo de la pulmonología ... en su Estudio RENEW, casi 3 meses antes ... prueba fundamental de exención de dispositivo de investigación ... y Medicamentos) para el sistema de espiral de ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... Oramed,Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ... today that its abstract, entitled "Open,Label Study ... (PD) of Five Oral Insulin Formulations in ... the upcoming 44th Annual,Meeting of the European ...
... MITI ), a biopharmaceutical company developing novel, ... autoimmune,diseases, will host a webcast and conference call ... Eastern Time (4:00 p.m. Central European,Time) to discuss ... Journal,SCIENCE on August 15, 2008., To access ...
Cached Medicine Technology:Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome) 2Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 2Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 3Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 4
(Date:10/22/2014)... Angeles, California (PRWEB) October 22, 2014 Hay ... 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) ... field of Yoga & Recovery. This book is meant ... thrive in a life of recovery. , Recovery 2.0 ... the 12 Steps; Recovery 2.0 is a guide for what ...
(Date:10/22/2014)... Plano, Texas (PRWEB) October 22, 2014 ... convenience of completing their continuing education at home ... now have access to 20 brand new, premium ... HomeCEUConnection.com’s robust catalog of over 2,000 hours ... to fully customize their educational experience. With such ...
(Date:10/22/2014)... of Prussia, PA (PRWEB) October 22, 2014 ... is recognized as an industry leader with over 25 ... award winning team leader in the areas related to ... addition, Mr. Carlson is an Editorial Advisory Board member ... Healthcare Council Educator. Blue Fin Group is a ...
(Date:10/22/2014)... -- Two sisters in high school have developed ways ... Medha Krishen use electronic stethoscopes, which electronically amplify body ... patterns or heartbeats. Ilina, a senior at Port ... a way to detect early lung damage in people ... Ilina recorded one breath cycle each from 16 smokers, ...
(Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... named,Richard L. Wonsettler to the newly created position of ... Wonsettler, who has nearly 20 years of financial,management experience ... that Cohera Medical is preparing to enter the clinical ... "We are entering an important phase in the ...
... 30 /PRNewswire-FirstCall/ - SXC Health Solutions Corp.,("SXC" or ... a leading provider of,technology and pharmacy benefits management ... for its informedRx(R) pharmacy benefit management,("PBM") services with ... begin providing its services for more than 6,000 ...
... Response by End of Week -, LAVAL, ... DDS;,NASDAQ: DDSS) today announced that the Company has ... Administration (FDA) regarding its most recent,appeal of the ... once-daily,tramadol formulation through the Formal Dispute Resolution process., ...
... national investigation of the drug called Diditek. In April ... UDL Laboratories Digitek (digoxin tablets, USP, all strengths) for ... time many consumers or their families have received notification ... to talk to any consumer who took this drug ...
... new assistive technology developed by engineers at the ... severe disabilities lead more independent lives. , ... operate a computer, control a powered wheelchair and ... tongues. , "This device could revolutionize the field ...
... are twice as likely to develop rheumatoid arthritis in ... ahead of print in the Annals of the ... origin of disease theory, which argues that certain conditions ... during the pregnancy. , Diabetes, coronary heart disease, and ...
Cached Medicine News:Health News:Cohera Medical Names Richard L. Wonsettler as Company's First CFO 2Health News:The University of Toledo selects SXC Health Solutions (informedRx) to provide pharmacy benefit management services 2Health News:The University of Toledo selects SXC Health Solutions (informedRx) to provide pharmacy benefit management services 3Health News:Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product 2Health News:Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product 3Health News:US Drug Watchdog Expands Its National Investigation Into The Drug Called Digitek, And Would Like To Talk To Possible Victims 2Health News:US Drug Watchdog Expands Its National Investigation Into The Drug Called Digitek, And Would Like To Talk To Possible Victims 3Health News:Tongue Drive system lets persons with disabilities operate powered wheelchairs, computers 2Health News:Tongue Drive system lets persons with disabilities operate powered wheelchairs, computers 3Health News:Tongue Drive system lets persons with disabilities operate powered wheelchairs, computers 4
MONOJECT Red/Yellow Mottled Stopper...
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
BD Vacutainer® Fluoride Tubes - Plastic...
Medicine Products: